{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T21:22:52Z","timestamp":1780435372666,"version":"3.54.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T00:00:00Z","timestamp":1652313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T00:00:00Z","timestamp":1652313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"tibet cheezheng tibetan medicine co., ltd.","award":["not applicable"],"award-info":[{"award-number":["not applicable"]}]},{"name":"Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine","award":["ZYYCXTD-C-202006"],"award-info":[{"award-number":["ZYYCXTD-C-202006"]}]},{"name":"Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine","award":["ZYYCXTD-C-202006"],"award-info":[{"award-number":["ZYYCXTD-C-202006"]}]},{"name":"Project of Methodological research combining quantitative and qualitative research on the effects and risks of Chinese patent medicines","award":["2180072120104"],"award-info":[{"award-number":["2180072120104"]}]},{"name":"Project of Methodological research combining quantitative and qualitative research on the effects and risks of Chinese patent medicines","award":["2180072120104"],"award-info":[{"award-number":["2180072120104"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Acute gouty arthritis (AGA) is an inflammatory arthritis clinically characterized by severe pain, swelling, and restricted movement of joints, which may cause physical disability and decrease quality of life. The use of recommended first-line treatment agents for AGA may be limited by adverse events. There has been a traditional use of alternative therapies for AGA. Tibetan medicine Qingpeng ointment is one of the on-market herbal products used for symptom relief of AGA. Previous clinical studies indicated that Qingpeng ointment can relieve pain, swelling, redness, and dysfunction of joints in patients with AGA. However, there is no rigorous randomized trial to demonstrate its benefit for AGA. In order to evaluate the efficacy and safety of Qingpeng ointment for AGA, we designed a randomized controlled trial.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This study is designed as a multi-center, randomized, double-blind, placebo-controlled trial. Two hundred and six adults with acute flare of gout, and visual analogue scale (VAS) score of joint pain \u2265 3 points will be recruited. Participants will be randomly assigned to herbal treatment or placebo group at a ratio of 1:1. Qingpeng ointment, or equal placebo ointment, will be applied topically at involved joints twice a day for consecutive 7 days. Patients in both groups would be allowed giving diclofenac sodium sustained-release tablets as rescue therapy when VAS score of joint pain \u2265 7 points during the treatment. The primary outcomes will be joint pain measured by VAS score, and joint swelling measured using width and thickness of affected joints and VAS score. Other outcome measures will be joint mobility, joint redness, C-reactive protein, serum uric acid, and the use of rescue medicine as well as adverse effect.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>To the best of our knowledge, this study is the first multi-center, randomized, double-blind, and placebo-controlled clinical trial to assess the efficacy of Tibetan medicine Qingpeng ointment for AGA. The findings of this study would provide evidence for its use to relieve symptoms of AGA.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>ISRCTN <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.isrctn.com\/ISRCTN34355813\">ISRCTN34355813<\/jats:ext-link>. Registered on 25 January 2021<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-022-06338-1","type":"journal-article","created":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T11:04:04Z","timestamp":1652353444000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Efficacy and safety of Tibetan medicine Qingpeng ointment for acute gouty arthritis: protocol for a multi-center, randomized, double-blind, placebo-controlled trial"],"prefix":"10.1186","volume":"23","author":[{"given":"Ya-xi","family":"Shang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-min","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-peng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-chang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-yong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-feng","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-ping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,12]]},"reference":[{"issue":"3s","key":"6338_CR1","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1016\/j.semarthrit.2020.04.008","volume":"50","author":"JA Singh","year":"2020","unstructured":"Singh JA, Gaffo A. Gout epidemiology and comorbidities. Semin Arthritis Rheum. 2020;50(3s):S11\u2013s16.","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"6338_CR2","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1002\/art.40807","volume":"71","author":"M Chen-Xu","year":"2019","unstructured":"Chen-Xu M, Yokose C, Rai SK, Pillinger MH, Choi HK. Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: the National Health and Nutrition Examination Survey, 2007-2016. Arthritis Rheum. 2019;71(6):991\u20139.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"6338_CR3","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.semarthrit.2016.08.006","volume":"46","author":"SK Rai","year":"2017","unstructured":"Rai SK, Avi\u00f1a-Zubieta JA, McCormick N, De Vera MA, Shojania K, Sayre EC, et al. The rising prevalence and incidence of gout in British Columbia, Canada: Population-based trends from 2000 to 2012. Semin Arthritis Rheum. 2017;46(4):451\u20136.","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"6338_CR4","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/acr.22660","volume":"68","author":"T Bardin","year":"2016","unstructured":"Bardin T, Bou\u00e9e S, Clerson P, Chal\u00e8s G, Flipo RM, Liot\u00e9 F, et al. Prevalence of gout in the adult population of France. Arthritis Care Res (Hoboken). 2016;68(2):261\u20136.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"6338_CR5","first-page":"762820","volume":"2015","author":"R Liu","year":"2015","unstructured":"Liu R, Han C, Wu D, Xia X, Gu J, Guan H, et al. Prevalence of hyperuricemia and gout in mainland China from 2000 to 2014: a systematic review and meta-analysis. Biomed Res Int. 2015;2015:762820.","journal-title":"Biomed Res Int"},{"issue":"9","key":"6338_CR6","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1111\/j.1445-5994.2012.02794.x","volume":"42","author":"PC Robinson","year":"2012","unstructured":"Robinson PC, Taylor WJ, Merriman TR. Systematic review of the prevalence of gout and hyperuricaemia in Australia. Intern Med J. 2012;42(9):997\u20131007.","journal-title":"Intern Med J"},{"issue":"7","key":"6338_CR7","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1093\/rheumatology\/kez476","volume":"59","author":"Y Xia","year":"2020","unstructured":"Xia Y, Wu Q, Wang H, Zhang S, Jiang Y, Gong T, et al. Global, regional and national burden of gout, 1990-2017: a systematic analysis of the Global Burden of Disease Study. Rheumatology (Oxford). 2020;59(7):1529\u201338.","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"6338_CR8","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1093\/rheumatology\/ket265","volume":"52","author":"P Chandratre","year":"2013","unstructured":"Chandratre P, Roddy E, Clarson L, Richardson J, Hider SL, Mallen CD. Health-related quality of life in gout: a systematic review. Rheumatology (Oxford). 2013;52(11):2031\u201340.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"6338_CR9","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/acr.24180","volume":"72","author":"JD FitzGerald","year":"2020","unstructured":"FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care Res (Hoboken). 2020;72(6):744\u201360.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"6338_CR10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","volume":"76","author":"P Richette","year":"2017","unstructured":"Richette P, Doherty M, Pascual E, Barskova V, Becce F, Casta\u00f1eda-Sanabria J, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29\u201342.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"6338_CR11","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.amjmed.2010.09.012","volume":"124","author":"RT Keenan","year":"2011","unstructured":"Keenan RT, O'Brien WR, Lee KH, Crittenden DB, Fisher MC, Goldfarb DS, et al. Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am J Med. 2011;124(2):155\u201363.","journal-title":"Am J Med"},{"issue":"1","key":"6338_CR12","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13075-020-2120-7","volume":"22","author":"S Stewart","year":"2020","unstructured":"Stewart S, Yang KCK, Atkins K, Dalbeth N, Robinson PC. Adverse events during oral colchicine use: a systematic review and meta-analysis of randomised controlled trials. Arthritis Res Ther. 2020;22(1):28.","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"6338_CR13","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.cgh.2014.11.007","volume":"13","author":"\u00c1 Lanas","year":"2015","unstructured":"Lanas \u00c1, Carrera-Lasfuentes P, Arguedas Y, Garc\u00eda S, Bujanda L, Calvet X, et al. Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory drugs, antiplatelet agents, or anticoagulants. Clin Gastroenterol Hepatol. 2015;13(5):906\u2013912.e902.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"14","key":"6338_CR14","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.2174\/1381612053764922","volume":"11","author":"HF Cheng","year":"2005","unstructured":"Cheng HF, Harris RC. Renal effects of non-steroidal anti-inflammatory drugs and selective cyclooxygenase-2 inhibitors. Curr Pharm Des. 2005;11(14):1795\u2013804.","journal-title":"Curr Pharm Des"},{"issue":"4","key":"6338_CR15","doi-asserted-by":"publisher","first-page":"e014603","DOI":"10.1136\/bmjopen-2016-014603","volume":"7","author":"R Costello","year":"2017","unstructured":"Costello R, Patel R, Humphreys J, McBeth J, Dixon WG. Patient perceptions of glucocorticoid side effects: a cross-sectional survey of users in an online health community. BMJ Open. 2017;7(4):e014603.","journal-title":"BMJ Open"},{"issue":"1","key":"6338_CR16","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s11655-014-1893-4","volume":"21","author":"H Luo","year":"2015","unstructured":"Luo H. Traditional Tibetan medicine in China: an overview of current status and prospects. Chin J Integr Med. 2015;21(1):67\u201370.","journal-title":"Chin J Integr Med"},{"issue":"2","key":"6338_CR17","first-page":"326","volume":"41","author":"MR Jia","year":"2010","unstructured":"Jia MR, Zhang Y, Du J. Characteristics and sustainable development of Tibetan medicine. Chin Tradit Herb Drugs. 2010;41(2):326\u20139.","journal-title":"Chin Tradit Herb Drugs"},{"issue":"9","key":"6338_CR18","first-page":"126","volume":"7","author":"Q Jiang","year":"2017","unstructured":"Jiang Q. Clinical analysis of Qingpeng ointment and etoricoxib in the treatment of gout. J Front Med. 2017;7(9):126.","journal-title":"J Front Med"},{"issue":"33","key":"6338_CR19","first-page":"4217","volume":"20","author":"CZ Yu","year":"2011","unstructured":"Yu CZ, Xu XM, Liu X, Yan Z. Observation on the efficacy of Qingpeng ointment combined with etoricoxib in the treatment of gouty arthritis. Mod J Integr Tradit Chin West Med. 2011;20(33):4217\u20138.","journal-title":"Mod J Integr Tradit Chin West Med"},{"issue":"22","key":"6338_CR20","first-page":"19","volume":"6","author":"QN Luo","year":"2011","unstructured":"Luo QN, Wu MQ. Contrastive study of the Qizheng Qing Peng ointment in the treatment of gouty arthritis. China Prac Med. 2011;6(22):19\u201320.","journal-title":"China Prac Med"},{"issue":"32","key":"6338_CR21","first-page":"157","volume":"49","author":"CF Lou","year":"2011","unstructured":"Lou CF. Clinical observation on 36 cases acute gouty arthritis treated with Qingpeng ointment combined diclofenac. Chin Mod Doct. 2011;49(32):157\u20138.","journal-title":"Chin Mod Doct"},{"issue":"5","key":"6338_CR22","first-page":"774","volume":"33","author":"YL Liu","year":"2011","unstructured":"Liu YL. Clinical observation on the treatment of acute gouty arthritis by external application of Qingpeng ointment. Hebei Med J. 2011;33(5):774\u20135.","journal-title":"Hebei Med J"},{"issue":"12","key":"6338_CR23","first-page":"755","volume":"19","author":"JB Wang","year":"2006","unstructured":"Wang JB, Xie RA, Jiang XB, Pan L, Liang HD. Clinical investigation on the treatment of acute gouty arthritis with Qingpeng paste. Chin J Orthopa Trauma. 2006;19(12):755\u20136.","journal-title":"Chin J Orthopa Trauma"},{"issue":"4","key":"6338_CR24","first-page":"285","volume":"28","author":"PT Jia","year":"2009","unstructured":"Jia PT, Zhang XL, Zhang GD. Observation on the therapeutic effect of Qizheng Qingpeng ointment on knee osteoarthritis Proc. Clin Med. 2009;28(4):285\u20137.","journal-title":"Clin Med"},{"issue":"5","key":"6338_CR25","first-page":"316","volume":"19","author":"YX Zheng","year":"2006","unstructured":"Zheng YX, Zhan HS, Zhang H, Niu SG, Zhuang ZJ. Qi-zheng Qingpeng ointment for treatment of the knee osteoarthritis: a randomized, controlled clinical research. Chin J Orthop Trauma. 2006;19(5):316\u20137.","journal-title":"Chin J Orthop Trauma"},{"issue":"12","key":"6338_CR26","first-page":"917","volume":"22","author":"CY Zhou","year":"2009","unstructured":"Zhou CY, Pan Z, Ma F, Tang JY. Controlled clinical trials of external using of Cheezheng Qingpeng ointment on relieving analgesia and swelling for the treatment of rheumatoid arthritis. Chin J Orthop Trauma. 2009;22(12):917\u20139.","journal-title":"Chin J Orthop Trauma"},{"issue":"10","key":"6338_CR27","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1136\/annrheumdis-2015-208237","volume":"74","author":"T Neogi","year":"2015","unstructured":"Neogi T, Jansen TL, Dalbeth N, Fransen J, Schumacher HR, Berendsen D, et al. 2015 Gout classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2015;74(10):1789\u201398.","journal-title":"Ann Rheum Dis"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06338-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-022-06338-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06338-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T11:23:30Z","timestamp":1652354610000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-022-06338-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,12]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["6338"],"URL":"https:\/\/doi.org\/10.1186\/s13063-022-06338-1","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,12]]},"assertion":[{"value":"11 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study has obtained the ethics approval from the Ethics Committee of Fangshan Hospital, Beijing University of Chinese Medicine on September 18, 2020 (Reference No. FZY LK-2020-015); from the Ethics Committee of The Second Affiliated Hospital of Zhejiang Chinese Medical University on January 26, 2021 (Reference No. 2020-Y-003-IH01); and from the Ethics Committee of Liuzhou People\u2019s Hospital on April 26, 2021 (Reference No. GCP2021-015-01). Before participating, all participants will be fully informed of the trial and sign an informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"387"}}